Literature DB >> 7734458

A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification.

L Amass1, W K Bickel, S T Higgins, J R Hughes.   

Abstract

Eight opioid-dependent individuals were maintained on daily sublingual buprenorphine (8 mg) for 28 days and assigned randomly to one of two outpatient detoxification schedules under double-blind, double-dummy conditions. The two detoxification schedules were buprenorphine gradual (36 days; N = 3) or buprenorphine rapid (12 days; N = 5). Outcome variables were subject- and observer-ratings of opioid withdrawal, treatment retention and illicit-opioid use. Outcome measures were similar for the two groups during buprenorphine maintenance. Increases in subject-rated opioid withdrawal and illicit-opioid use, and a drop in treatment retention occurred during rapid detoxification. Stable subject-rated opioid withdrawal and treatment retention, and less illicit-opioid use occurred during gradual detoxification. These data suggest that gradual reduction in buprenorphine dose is likely to produce superior treatment outcomes than more rapid buprenorphine detoxification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7734458     DOI: 10.1300/j069v13n03_04

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  28 in total

Review 1.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

2.  Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Miller; Paul A Nuzzo; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2015-03-12       Impact factor: 4.492

3.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

Review 4.  Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.

Authors:  Jacob T Borodovsky; Sharon Levy; Marc Fishman; Lisa A Marsch
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

Review 5.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

6.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

7.  Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Authors:  T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

8.  Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Authors:  Stacey C Sigmon; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins
Journal:  Addict Behav       Date:  2008-11-24       Impact factor: 3.913

9.  Buprenorphine for opioid dependence.

Authors:  Walter Ling
Journal:  Expert Rev Neurother       Date:  2009-05       Impact factor: 4.618

Review 10.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.